Nymox Pharmaceutical News (NASDAQ:NYMX)

DateTimeSource
Headline
11/27/201711:00AMGLOBENymox Fexapotide Symposium and Panel Discussion at American Urological Association South Central Sectional Annual Meeting in ...
HASBROUCK HEIGHTS, N.J., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, South Central Section in Naples, November 27. The abstract from the... More...>>
11/16/201711:10AMGLOBENymox Fexapotide Symposium and Panel Discussion at American Urological Association North Central Sectional Annual Meeting in ...
HASBROUCK HEIGHTS, N.J., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, North Central Section in Scottsdale, November 15. The abstract from... More...>>
11/10/201710:30AMGLOBESymposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association North Central Section Annu...
HASBROUCK HEIGHTS, N.J., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report that a Symposium on Fexapotide Triflutate studies will be held at the Annual Meeting of the American Urological Association North Central Section, in Scottsdale AZ next week. The symposium, “Fexapotide... More...>>
11/07/201711:15AMGLOBENymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New Yor...
HASBROUCK HEIGHTS, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report on the two data presentations which were held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, New York Section in Havana, November 6.  The abstract... More...>>
10/26/201712:15PMGLOBENymox Announces Two Data Presentations for Company's BPH Drug at New York American Urological Association Meeting November 6
HASBROUCK HEIGHTS, N.J., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that two data presentations of the Company's new drug Fexapotide Triflutate will be held at the November meeting of the American Urological Association, New York Section. The November 6 presentations... More...>>
10/13/20179:37AMGLOBENymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Section...
HASBROUCK HEIGHTS, N.J., Oct. 13, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, Northeast Section in Savannah, October 12 at 4 pm. The abstract from... More...>>
10/10/201710:00AMGLOBENymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual M...
HASBROUCK HEIGHTS, N.J., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report on the Symposium on Fexapotide Triflutate studies to be held at the Annual Meeting of the American Urological Association Northeastern Section, in Savannah GA this week. The symposium, “Fexapotide... More...>>
09/25/201710:30AMGLOBENymox Announces October 12 Symposium for Company's BPH Drug at American Urological Association Meeting
HASBROUCK HEIGHTS, N.J., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that an important large symposium and panel assessment of the Company's new drug Fexapotide Triflutate will be held at the October meeting of the American Urological Association, Northeast Section... More...>>
09/14/201712:40PMGLOBENymox Application Validated:
HASBROUCK HEIGHTS, N.J., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce today that the European Member States for Nymox's Marketing Authorization Application (MAA) for Fexapotide Triflutate for the treatment of benign prostatic hyperplasia (BPH, prostate enlargement... More...>>
09/14/201710:00AMGLOBENymox Announces New Symposium for Company's BPH Drug at American Urological Association Meeting October 5
HASBROUCK HEIGHTS, N.J., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that an important large symposium and panel assessment of the Company's new drug Fexapotide Triflutate will be held at the October meeting of the American Urological Association, South Central... More...>>
09/11/201712:15PMGLOBEAUA Meeting in Florida September 16 Postponed Due to Hurricane
HASBROUCK HEIGHTS, N.J., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) The September 16 AUA Meeting in Amelia Island, Florida has been postponed due to the hurricane disaster in Florida.  The Company wishes the very best for all persons in harm's way and salutes the efforts of the thousands... More...>>
08/09/201710:30AMGLOBENymox Announces Private Placements of $3 Million
HASBROUCK HEIGHTS, N.J., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce recent completion of private placements with proceeds totaling US $3.0 million. There were no warrants or fees associated with the transactions. The placements were with long-term shareholders... More...>>
08/07/201710:00AMGLOBENymox Announces Symposium for Company's BPH Drug at American Urological Association Meeting in September
HASBROUCK HEIGHTS, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that an important large symposium and panel assessment of the Company's new drug Fexapotide Triflutate will be held at the September meeting of the American Urological Association, Mid-Atlantic... More...>>
05/31/201710:00AMGLOBESexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical Trials
HASBROUCK HEIGHTS, N.J., May 31, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce statistically significant clinical trial results showing that the Company's prostate enlargement (BPH) and prostate cancer drug Fexapotide Triflutate produced clinically important improvements... More...>>
05/10/201711:15AMGLOBENYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 EDT
HASBROUCK HEIGHTS, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) will hold a teleconference call for shareholders today May 10 at 4:30 EDT. The call in number is 1-888-424-8151 and the passcode is 7826703# (for Canada please use 1-888-465-5079). Forward Looking Statements To the... More...>>
05/08/201711:00AMGLOBENYMOX Files For Approval of First In Class Prostate Drug in Europe: Company To Hold Teleconference Wednesday May 10 at 4:30 E...
HASBROUCK HEIGHTS, N.J., May 08, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Following Nymox's announcement of the Company's filing for marketing approval of Fexapotide Triflutate for enlarged prostate (BPH) in Europe, Nymox is pleased to announce a teleconference with shareholders at 4:30 p.m... More...>>
05/03/20179:30AMGLOBENYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe
HASBROUCK HEIGHTS, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce today that the Company has filed to seek approval for marketing authorization for Fexapotide Triflutate in five European countries, comprising the Netherlands, the UK, Germany, France and Spain... More...>>
03/29/201710:45AMGLOBENymox Provides Update on Fexapotide Development
HASBROUCK HEIGHTS, N.J., March 29, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) provided an update today on the Company's development activities for Fexapotide Triflutate, its new drug for prostate enlargement. The Company is very pleased with the progress it has made, which is in line... More...>>
11/29/20169:45AMGLOBENymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response an...
HASBROUCK HEIGHTS, N.J., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that new Phase 3 prospective randomized clinical trial results have confirmed that patients who received fexapotide as their initial treatment for BPH (prostate enlargement) had superior efficacy... More...>>
10/11/201610:00AMGLOBENymox Reports Successful New Phase 3 Long-Term Fexapotide Repeat Injection BPH Trial Results: Lasting Symptomatic Improvement...
HASBROUCK HEIGHTS, N.J., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce successful new study results from the long-term repeated injection group from the U.S. Phase 3 trials for fexapotide, the Company's lead compound in late stage development... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V:us D:20171217 02:23:12